https://www.fiercebiotech.com/biotech/astellas-adds-cullgen-parade-protein-degrader-pacts-paying-35m-upfront-access-tech
Astellas pays Cullgen $35M upfront to form protein degrader pact
Jun 15, 2023 - After hustling an in-house KRAS candidate into the clinic, Astellas has agreed to pay Cullgen $35 million upfront to access new prospects.
to formastellaspayscullgenupfront
https://www.businesswire.com/news/home/20230508005341/en/Cullgen-Raises-%2440-Million-in-New-Financing-Led-by-AstraZeneca-CICC-Fund
Cullgen Raises $40 Million in New Financing Led by AstraZeneca-CICC Fund
Cullgen Raises $40 Million in New Financing Led by AstraZeneca-CICC Fund
https://www.law360.com/healthcare-authority/articles/2447478/gyre-cullgen-merge-in-300m-all-stock-deal
Gyre, Cullgen Merge In $300M All-Stock Deal - Law360 Healthcare Authority
Commercial-stage biopharmaceutical company Gyre Therapeutics Inc. on Monday announced plans to acquire clinical-stage biopharmaceutical company Cullgen Inc. in...
all stockgyrecullgenmerge300m
https://www.cullgen.com/
Cullgen
cullgen